Evaxion AS Stock Price, News & Analysis

Evaxion (NASDAQ: EVAX) reported Q1 2025 financial results and provided business updates. Key highlights include: EVX-01 phase 2 trial progression with 80% of vaccine targets triggering tumor-specific immune responses, significantly higher than comparable vaccines. The company's cash position improved to $17.8 million as of March 31, 2025, from $6.0 million in December 2024, extending runway to mid-2026. Q1 2025 showed a net loss of $1.6 million ($0.01 per share) compared to net income of $1.2 million in Q1 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year. The company expects potential value catalysts in H2 2025, including EVX-01 two-year data readout and possible MSD option exercise for EVX-B2 and EVX-B3 programs. Evaxion is targeting at least two new partnership agreements in 2025, though market conditions may impact timing.

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q1 2025 financial results announcement and business update for May 27, 2025, before Nasdaq CM market opening. The company's management will host a conference call and webcast at 14:30 CET/08:30 EST on the same day. Investors and the public can participate in the event by registering in advance to receive dial-in details and a PIN code. The presentation will be followed by a Q&A session, and a recording will be made available on Evaxion's website after the event.

Evaxion (NASDAQ: EVAX) has initiated a one-year extension of its Phase 2 trial for EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma. The first patient has received treatment in this extension phase, which will evaluate EVX-01 as a monotherapy following its initial two-year combination with checkpoint inhibitors. The extension aims to assess long-term benefits with minimal additional costs. The original Phase 2 trial has shown promising results, with 69% Overall Response Rate and tumor reduction in 15 out of 16 patients at the one-year mark. Notably, 80% of EVX-01's vaccine targets successfully triggered immune responses. The trial extension will provide insights into treatment durability for up to three years, with two-year data expected in H2 2025.

Evaxion Biotech (NASDAQ: EVAX) has presented compelling new data for its personalized cancer vaccine EVX-01 at the AACR Annual Meeting. The vaccine, designed using AI-Immunology™ platform, demonstrated an impressive 80% tumor-specific immune response rate among vaccine targets, surpassing previously reported rates of 71% and 79% at ASCO and ESMO 2024 meetings.

The ongoing phase 2 trial evaluates EVX-01 in combination with KEYTRUDA® for advanced melanoma treatment. The immune response data shows strong and sustained results, with enhanced effects from booster immunizations. The trial, which previously showed strong one-year interim clinical data, is progressing toward its two-year data readout in H2 2025 and has been extended for a third year for comprehensive assessment.

Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company, will showcase its AI-Immunology™ platform at the World Vaccine Congress in Washington, D.C., from April 21-24, 2025. The company will deliver two key presentations and host booth #351.

Chief Scientific Officer Birgitte Rønø will present on AI-powered antigen target discovery for cancer vaccines on April 23 at 11:40 ET in Room 206. Additionally, Pär Comstedt, VP of Infectious Disease Vaccine Development, will discuss AI-powered target discovery for infectious disease vaccines at 15:10 ET in Room 202b.

This congress marks one of several scientific, partnering, and investor conferences where Evaxion plans to engage with potential partners and collaborators in Q2 2025. The company will demonstrate its AI-Immunology™ platform's capabilities in vaccine development for both cancers and infectious diseases.

Evaxion Biotech (NASDAQ: EVAX) reported its full year 2024 financial results and business updates. The company's partnership with MSD on two vaccine candidates is progressing towards potential option exercise in H2 2025. Their lead asset EVX-01, a personalized cancer vaccine, showed promising one-year interim data with a 69% Overall Response rate.

Financial highlights include revenue of $3.3 million in 2024 (vs $0.1M in 2023), reduced net loss of $10.6 million (vs $22.1M in 2023), and successful capital raising of approximately $17 million in early 2025. R&D expenses decreased to $10.5 million from $11.9 million in 2023.

Key 2025 milestones include two-year clinical efficacy readout for EVX-01, potential MSD option exercise worth up to $10 million, selection of lead ERV-based precision cancer vaccine candidate, and at least two new business development agreements.

Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, has scheduled its full year 2024 financial results announcement and business update for April 1, 2025, before Nasdaq CM market opening.

The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST. The event will be free and open to the public, featuring a presentation of results followed by a Q&A session. Participants must register in advance to receive dial-in details and a unique PIN code. A recording of the webcast will be made available on Evaxion's website after the event.

Evaxion Biotech (NASDAQ: EVAX) will present new biomarker and immune data from its ongoing phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma, at the upcoming AACR Annual Meeting in Chicago (April 25-30, 2025).

The presentation will focus on T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving EVX-01 in combination with KEYTRUDA® (pembrolizumab). The trial has previously shown strong interim one-year clinical data and is on track for two-year clinical data readout in H2 2025. The study has been extended for a third year to allow for a more comprehensive assessment.

The poster presentation is scheduled for April 29, 2025, from 9am-12pm CST at the AACR Annual Meeting, highlighting the company's AI-Immunology™ powered vaccine technology.

Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, has announced its participation in multiple scientific and investor conferences across the US and Europe during March-June 2025.

The company will deliver scientific and corporate updates at key events including:

• Immunotherapy and Immuno-Oncology Congress in London (March 12-14)
• HC Wainwright AI Based Drug Discovery Conference (Virtual, April 2)
• World Vaccine Congress in Washington (April 21-25)
• AACR Annual Meeting in Chicago (April 25-30)
• BIO International Convention in Boston (June 16-19)

These conferences are strategically important for Evaxion to identify potential business partnerships and scientific collaborations. The company will also attend additional conferences without presenting to enhance stakeholder engagement.